Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266929 | 0.87 | PPARD (0.54) | PPARDMAPTPPARGLTB4RLTB4R2 | |
| SCHEMBL31155854 | 0.87 | PPARD (0.54) | PPARDMAPTPPARGLTB4RLTB4R2 | |
| SCHEMBL9122500 | 0.86 | PPARD (0.53) | PPARDPPARGLTB4RLTB4R2 | |
| SCHEMBL31155865 | 0.86 | PPARD (0.53) | PPARDMAPTPPARGLTB4RLTB4R2 | |
| SCHEMBL15927987 | 0.86 | PPARG (0.60) | PPARDMAPTPPARGLTB4RLTB4R2 | |
| SCHEMBL31155848 | 0.85 | PPARD (0.52) | PPARDMAPTPPARGLTB4RLTB4R2 | |
| SCHEMBL9119104 | 0.85 | PPARD (0.52) | PPARDMAPTPPARGLTB4RLTB4R2 | |
| SCHEMBL9121525 | 0.83 | PPARD (0.51) | PPARDPPARGLTB4RLTB4R2 | |
| SCHEMBL9118855 | 0.82 | PPARD (0.50) | PPARDPPARGLTB4RLTB4R2 | |
| SCHEMBL9121426 | 0.81 | PPARD (0.49) | PPARDPPARGLTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
| CN-101351448-A | Novel 1-benzyl-4-piperidinamines for the treatment of COPD and asthma | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | CN | disclosed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | PPARD 127/4885MAPT 3981/4885PPARG 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.